On a never-ending waiting list: toward equitable access to anti-retroviral treatment? Experiences from Zambia.
Universal access to anti-retroviral (ARV) medication for HIV/AIDS is the clarion call of the WHO/UNAIDS 3 by 5 Initiative. Treatment coverage, however, remains highly uneven. This sharpens the question of who exactly is accessing ARVs and whether access is challenging inequality or reinforcing it. Issues of distributive justice have long been debated in health policy, but the practical challenges of ARV distribution are relatively new. In exploring what a more equitable process of ARV distribution could involve, this article draws on a human rights framework using case study material from Zambia.
Jones
Peris Sean
PS
Norwegian Centre for Human Rights. peris.jones@nchr.uio.no
D019380:Anti-HIV Agents / Q000191:economics / Q000600:supply & distribution* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D015276:Health Care Rationing / Q000458:organization & administration; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration*; D006806:Human Rights; D006801:Humans; D018579:Patient Selection; D011057:Politics; D014850:Waiting Lists; D014944:World Health Organization; D015024:Zambia / Q000453:epidemiology
D019380:Anti-HIV Agents